169 related articles for article (PubMed ID: 29018201)
1. Activating de novo mutations in NFE2L2 encoding NRF2 cause a multisystem disorder.
Huppke P; Weissbach S; Church JA; Schnur R; Krusen M; Dreha-Kulaczewski S; Kühn-Velten WN; Wolf A; Huppke B; Millan F; Begtrup A; Almusafri F; Thiele H; Altmüller J; Nürnberg P; Müller M; Gärtner J
Nat Commun; 2017 Oct; 8(1):818. PubMed ID: 29018201
[TBL] [Abstract][Full Text] [Related]
2. Recurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers.
Goldstein LD; Lee J; Gnad F; Klijn C; Schaub A; Reeder J; Daemen A; Bakalarski CE; Holcomb T; Shames DS; Hartmaier RJ; Chmielecki J; Seshagiri S; Gentleman R; Stokoe D
Cell Rep; 2016 Sep; 16(10):2605-2617. PubMed ID: 27568559
[TBL] [Abstract][Full Text] [Related]
3. Nuclear factor erythroid 2-like 2 (Nrf2) expression in end-stage liver disease.
Kurzawski M; Dziedziejko V; Urasińska E; Post M; Wójcicki M; Miętkiewski J; Droździk M
Environ Toxicol Pharmacol; 2012 Jul; 34(1):87-95. PubMed ID: 22459801
[TBL] [Abstract][Full Text] [Related]
4. Nrf2 activators attenuate the progression of nonalcoholic steatohepatitis-related fibrosis in a dietary rat model.
Shimozono R; Asaoka Y; Yoshizawa Y; Aoki T; Noda H; Yamada M; Kaino M; Mochizuki H
Mol Pharmacol; 2013 Jul; 84(1):62-70. PubMed ID: 23592516
[TBL] [Abstract][Full Text] [Related]
5. Nrf2 protects against airway disorders.
Cho HY; Kleeberger SR
Toxicol Appl Pharmacol; 2010 Apr; 244(1):43-56. PubMed ID: 19646463
[TBL] [Abstract][Full Text] [Related]
6. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma.
Ooi A; Dykema K; Ansari A; Petillo D; Snider J; Kahnoski R; Anema J; Craig D; Carpten J; Teh BT; Furge KA
Cancer Res; 2013 Apr; 73(7):2044-51. PubMed ID: 23365135
[TBL] [Abstract][Full Text] [Related]
7. Nrf2: friend and foe in preventing cigarette smoking-dependent lung disease.
Müller T; Hengstermann A
Chem Res Toxicol; 2012 Sep; 25(9):1805-24. PubMed ID: 22686525
[TBL] [Abstract][Full Text] [Related]
8. Keap1/Nrf2 signaling regulates oxidative stress tolerance and lifespan in Drosophila.
Sykiotis GP; Bohmann D
Dev Cell; 2008 Jan; 14(1):76-85. PubMed ID: 18194654
[TBL] [Abstract][Full Text] [Related]
9. Molecular mechanisms for the regulation of Nrf2-mediated cell proliferation in non-small-cell lung cancers.
Yamadori T; Ishii Y; Homma S; Morishima Y; Kurishima K; Itoh K; Yamamoto M; Minami Y; Noguchi M; Hizawa N
Oncogene; 2012 Nov; 31(45):4768-77. PubMed ID: 22249257
[TBL] [Abstract][Full Text] [Related]
10. Directly interact with Keap1 and LPS is involved in the anti-inflammatory mechanisms of (-)-epicatechin-3-gallate in LPS-induced macrophages and endotoxemia.
Chiou YS; Huang Q; Ho CT; Wang YJ; Pan MH
Free Radic Biol Med; 2016 May; 94():1-16. PubMed ID: 26878775
[TBL] [Abstract][Full Text] [Related]
11. Keap1-Nrf2 signalling in pancreatic cancer.
Hayes AJ; Skouras C; Haugk B; Charnley RM
Int J Biochem Cell Biol; 2015 Aug; 65():288-99. PubMed ID: 26117456
[TBL] [Abstract][Full Text] [Related]
12. NRF2 and KEAP1 mutations: permanent activation of an adaptive response in cancer.
Hayes JD; McMahon M
Trends Biochem Sci; 2009 Apr; 34(4):176-88. PubMed ID: 19321346
[TBL] [Abstract][Full Text] [Related]
13. Association of NFE2L2 and KEAP1 haplotypes with amyotrophic lateral sclerosis.
Bergström P; von Otter M; Nilsson S; Nilsson AC; Nilsson M; Andersen PM; Hammarsten O; Zetterberg H
Amyotroph Lateral Scler Frontotemporal Degener; 2014 Mar; 15(1-2):130-7. PubMed ID: 24102512
[TBL] [Abstract][Full Text] [Related]
14. Association of KEAP1 and NFE2L2 polymorphisms with temporal lobe epilepsy and drug resistant epilepsy.
Liu Z; Yin X; Liu L; Tao H; Zhou H; Ma G; Cui L; Li Y; Zhang S; Xu Z; Yao L; Cai Z; Zhao B; Li K
Gene; 2015 Oct; 571(2):231-6. PubMed ID: 26149655
[TBL] [Abstract][Full Text] [Related]
15. miRNA-141 attenuates UV-induced oxidative stress via activating Keap1-Nrf2 signaling in human retinal pigment epithelium cells and retinal ganglion cells.
Cheng LB; Li KR; Yi N; Li XM; Wang F; Xue B; Pan YS; Yao J; Jiang Q; Wu ZF
Oncotarget; 2017 Feb; 8(8):13186-13194. PubMed ID: 28061435
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemical study of the Nrf2 pathway in colorectal cancer: Nrf2 expression is closely correlated to Keap1 in the tumor and Bach1 in the normal tissue.
Chang LC; Fan CW; Tseng WK; Chen JR; Chein HP; Hwang CC; Hua CC
Appl Immunohistochem Mol Morphol; 2013 Dec; 21(6):511-7. PubMed ID: 23455180
[TBL] [Abstract][Full Text] [Related]
17. Dysregulation of the Keap1-Nrf2 pathway in cancer.
Leinonen HM; Kansanen E; Pölönen P; Heinäniemi M; Levonen AL
Biochem Soc Trans; 2015 Aug; 43(4):645-9. PubMed ID: 26551706
[TBL] [Abstract][Full Text] [Related]
18. Oxaliplatin activates the Keap1/Nrf2 antioxidant system conferring protection against the cytotoxicity of anticancer drugs.
Wang XJ; Li Y; Luo L; Wang H; Chi Z; Xin A; Li X; Wu J; Tang X
Free Radic Biol Med; 2014 May; 70():68-77. PubMed ID: 24556415
[TBL] [Abstract][Full Text] [Related]
19. Amelioration of inflammation and tissue damage in sickle cell model mice by Nrf2 activation.
Keleku-Lukwete N; Suzuki M; Otsuki A; Tsuchida K; Katayama S; Hayashi M; Naganuma E; Moriguchi T; Tanabe O; Engel JD; Imaizumi M; Yamamoto M
Proc Natl Acad Sci U S A; 2015 Sep; 112(39):12169-74. PubMed ID: 26371321
[TBL] [Abstract][Full Text] [Related]
20. Activation of the Nrf2/ARE pathway via S-alkylation of cysteine 151 in the chemopreventive agent-sensor Keap1 protein by falcarindiol, a conjugated diacetylene compound.
Ohnuma T; Nakayama S; Anan E; Nishiyama T; Ogura K; Hiratsuka A
Toxicol Appl Pharmacol; 2010 Apr; 244(1):27-36. PubMed ID: 20026152
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
